Amsterdam 2020 Programme Information

To save session items, please click the heart icons. To view previously saved items, please click Load Favourites.


All Days Fri 20th Sat 21st Load Favourites
Programme Filter
timer Loading ... please wait
Thu 01

Vitreoretinal Surgery

Chairperson(s):A. Laidlaw UK,  J. Garcia-Arumi SPAIN-00.00 | Room:
Chairperson(s):
A. Laidlaw UK,  J. Garcia-Arumi SPAIN

Chairpersons: A. Laidlaw UKJ. Garcia-Arumi SPAIN

R. Hillier UK
Pneumatic retinopexy. Revisited

W. Heriot UK
Retinopexy Cryo or laser. Flat retina vs recently or currently detached retina, thermofusion. Evidence for and against

A. Laidlaw UK
Improving RRD outcomes: pre op posture, urgency of surgery for macula off RRD, preventing post op macula shift

B. Corcóstegui SPAIN
Encirclement in complex cases: Evidence, pros and cons

J. Garcia-Arumi SPAIN
Pathology of PVR, Anterior vs posteior membranes, When and How to peel PVR

T. Williamson UK
Retinectomy in PVR When and timing: early or delayed

J. Carlos Pastor SPAIN
Toxicity of intrasurgical medical devices: acute and chronic

TBC
Expected surgical outcomes: European and American registry studies

 

Panel Discussion

End of session

Thu 01

Late Breaking & Reviews

Chairperson(s):R. Tadayoni FRANCE-00.00 | Room:
Chairperson(s):
R. Tadayoni FRANCE

Chairpersons: R. Tadayoni FRANCE

Thu 01

Retinal Imaging, Artificial Intelligence, Big Data

Chairperson(s):S. Wolf SWITZERLAND,  N. Eter GERMANY-00.00 | Room:
Chairperson(s):
S. Wolf SWITZERLAND,  N. Eter GERMANY

Chairpersons: S. Wolf SWITZERLANDN. Eter GERMANY

TBC
Artificial Intelligence for retinal diseases

P. Keane UK
Artificial Intelligence in OCT and fundus images

T. Peto UK
Artificial Intelligence for DR screening

TBC
From DRSS to new imaging and AI

S. Sadda USA
Deep learning for assessment of AMD biomarkers

R. Schwartz UK
The role of deep learning and big data to analyze progression of AMD

 

Panel Discussion

End of session

Thu 01

Diabetic Retina

Chairperson(s):R. Schlingemann THE NETHERLANDS,  E. Midena ITALY-00.00 | Room:
Chairperson(s):
R. Schlingemann THE NETHERLANDS,  E. Midena ITALY

Chairpersons: R. Schlingemann THE NETHERLANDSE. Midena ITALY

A. Grzybowski POLAND
The role of reactive oxygen species and oxidative stress in the pathogenesis of diabetic retinopathy

E. Pilotto ITALY
Retinopathy in Type 1 diabetic children

A. Fawzi USA
Retinal blood flow in diabetic retinopathy

Francesco Bandello ITALY
Diabetic macular edema: toward a tailored treatment

M. Paques FRANCE
Deferred laser in DME: follow ETDRS or aim for TelCaps?

N. Bressler USA
Current and future DRCRnet protocols in diabetic retinopathy

A. Laidlaw UK
Surgical solutions for DR, when to go in

 

Panel Discussion

End of session

Thu 01

Decision Making in Challenging Cases

Chairperson(s):R. Schlingemann THE NETHERLANDS,  G. Querques ITALY-00.00 | Room:
Chairperson(s):
R. Schlingemann THE NETHERLANDS,  G. Querques ITALY

Chairpersons: R. Schlingemann THE NETHERLANDSG. Querques ITALY

C. Boon THE NETHERLANDS
A patient with severe chronic central serous chorioretinopathy

D. Sarraf USA
PAMM VS AMN: Brothers in Arms or Strangers in the Night

S. Sadda USA
PEVAC

R. Schlingemann THE NETHERLANDS
Retinal vascular abnormalities associated with leakage and hard exudates, Telcaps and others

B. Leroy BELGIUM
Decision making in rare hereditary retinal disease

TBC
Surgical challenge-subject TBD

Panel Discussion

End of session

 

Thu 01

RETINAWS

Chairperson(s):K. Rezaei USA,  R. Tadayoni FRANCE-00.00 | Room:
Chairperson(s):
K. Rezaei USA,  R. Tadayoni FRANCE

Chairpersons: K. Rezaei USAR. Tadayoni FRANCE

J. Garcia-Arumi SPAIN

X. Li CHINA

S. Priglinger GERMANY

G. Pertile ITALY

A. Maia BRAZIL

K. Kadonosono JAPAN

D. Steel UK

R. Tadayoni FRANCE

M. Berrocal PUERTO RICO

C. Claes BELGIUM

TBC

Panel Discussion

End of session

 

Thu 01

AMD

Chairperson(s):F. Holz GERMANY,  TBC-00.00 | Room:
Chairperson(s):
F. Holz GERMANY,  TBC

Chairpersons: F. Holz GERMANY, TBC

TBC
New insights from epidemiological studies

R. Finger GERMANY
Probing structure and function in early and intermediate AMD

TBC
Approaches to slow/halt progression of intermediate AMD

R. Spaide USA
State-of-the-art nomenclature for neovascular AMD

TBC
Novel therapeutic approaches for neovascular AMD

M. Zinkernagel SWITZERLAND
Artificial intelligence to detect biomarkers in OCT scans: Impact in managing AMD patients

A. Loewenstein ISRAEL
Improving adherence and outcomes in AMD therapy: Home monitoring

Panel Discussion

End of session

 

Thu 01

Retinal Vascular Diseases

Chairperson(s):A. Loewenstein ISRAEL,  N. Eter GERMANY-00.00 | Room:
Chairperson(s):
A. Loewenstein ISRAEL,  N. Eter GERMANY

Chairpersons: A. Loewenstein ISRAELN. Eter GERMANY

R. Schlingemann THE NETHERLANDS
New insights in the pathophysiology of diabetic macular edema & vein occlusion

P. Lanzetta ITALY
The management of DME & macular edema in vein occlusion

S. Sivaprasad UK
The management of PDR and neovascularization in vascular occlusion

J. Garcia-Arumi SPAIN
The surgical management of PDR & resistant cases of vein occlusion

F. Bandello ITALY
Is OCT-A essential in diabetic eyes?

U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in vascular retinal disease

M. Goldstein ISRAEL
Panel discussion: Retina vascular disease case

Panel Discussion

End of session

 

Fri 02

Retinal Gene Therapy: Present & Future

Chairperson(s):B. Leroy BELGIUM,  R. MacLaren UK-00.00 | Room:
Chairperson(s):
B. Leroy BELGIUM,  R. MacLaren UK

Chairpersons: B. Leroy BELGIUMR. MacLaren UK

Sat 03

Uveitis/Endophthalmitis

Chairperson(s):J. Garcia-Arumi SPAIN,  J. van Meurs THE NETHERLANDS-00.00 | Room:
Chairperson(s):
J. Garcia-Arumi SPAIN,  J. van Meurs THE NETHERLANDS

Chairpersons: J. Garcia-Arumi SPAINJ. van Meurs THE NETHERLANDS

TBC
Intravitreal treatment in noninfectious uveitis

B. Bodaghi FRANCE
Viral retinitis

A. Adan SPAIN
New strategies with biologics in uveitis 

F. Pichi UNITED ARAB EMIRATES
OCTA in uveitis

J. van Meurs THE NETHERLANDS
Earlier antibiotic treatment is the most feasible step to improve treatment of endophthalmitis

J. Garcia-Arumi SPAIN
Surgical treatment of endophthalmitis

 

Panel Discussion

End of session

Thu 01

Better patient counselling: Using epidemiological evidence in day to day clinical practice

Chairperson(s):C.C.W. Klaver THE NETHERLANDS,  R. Finger GERMANY-00.00 | Room:
Chairperson(s):
C.C.W. Klaver THE NETHERLANDS,  R. Finger GERMANY

Chairpersons: C.C.W. Klaver THE NETHERLANDSR. Finger GERMANY

C.C.W. Klaver THE NETHERLANDS
Myopia prevention

R. Finger GERMANY
AMD risk and progression

A. Schuster GERMANY
Glaucoma onset and progression

T. Peto UK
Diabetic eye diseases (DR & DME) onset, development of treatable stages, visual prognosis

C. Delcourt FRANCE
Diet and eye disease

 

Panel Discussion

End of session

Thu 01

Tumours

Chairperson(s):J.F. Kiilgaard DENMARK,  H. Heimann UK-00.00 | Room:
Chairperson(s):
J.F. Kiilgaard DENMARK,  H. Heimann UK

Chairpersons: J.F. Kiilgaard DENMARKH. Heimann UK

Thu 01

The EURETINA Guidelines for the Management of Retinal Disease: The Next Steps

Chairperson(s):U. Schmidt-Erfurth AUSTRIA,  A. Loewenstein ISRAEL-00.00 | Room:
Chairperson(s):
U. Schmidt-Erfurth AUSTRIA,  A. Loewenstein ISRAEL

Chairpersons: U. Schmidt-Erfurth AUSTRIAA. Loewenstein ISRAEL

TBC
Screening for AMD: Insight from latest AREDS analyses

U. Schmidt-Erfurth AUSTRIA
Neovascular AMD: AI evidence on novel grounds

S. Sivaprasad UK
Diabetic retinopathy severity: Diagnostic and therapeutic guidance

TBC
Surgery of (pseudo) holes: Standards in macular surgery

A. Loewenstein ISRAEL
Heads-up surgery: More options than ever

TBC 
The myopia pandemic: The European response

 

Panel Discussion

End of session

Thu 01

Research Session

Chairperson(s):C.C.W. Klaver THE NETHERLANDS,  M. Zinkernagel SWITZERLAND, R. Schlingemann THE NETHERLANDS-00.00 | Room:
Chairperson(s):
C.C.W. Klaver THE NETHERLANDS,  M. Zinkernagel SWITZERLAND, R. Schlingemann THE NETHERLANDS

Chairpersons: C.C.W. Klaver THE NETHERLANDSM. Zinkernagel SWITZERLAND, R. Schlingemann THE NETHERLANDS

TBC
New insights in retinal disease derived from the EyeRisk study

TBC 
How on earth could the gut microbiome influence eye disease?

TBC
Lessons learnt from single cell transcriptomics of the retina

TBC
Vascular-Glia-Neuron interactions in the retina

TBC
Is the causal role of inflammation in diabetic retinopathy still controversial?

TBC 
From screen to bedside: how to implement AI in the management of retinal disease?

 

Panel Discussion

End of session

Thu 01

Myopia Update 2020: Pathogenesis, Diagnosis & Treatment

Chairperson(s):X. Li CHINA,  R. Tadayoni FRANCE-00.00 | Room:
Chairperson(s):
X. Li CHINA,  R. Tadayoni FRANCE

Chairpersons: X. Li CHINAR. Tadayoni FRANCE

TBC
Impact of the morphologic characteristics of optic disc on choroidal thickness in young myopic patients

TBC 
Ultra wide-field imaging of pathologic myopia

X. Li CHINA
Transmissions of OCT in PIC, PIC-CNV and M-CNV

L. Chen CHINA
Update in myopic CNV treatment

L. Lu CHINA
Three years outcome of macular buckling for macularhole and foveoschisis in high myopic eyes

Y. Ikuno JAPAN
Surgical approach for myopic macular diseases

T. Ho TAIWAN
Thinking processes and practices in the management of vitreoretinal interface disorders in pathologic myopia

 

Panel Discussion

End of session

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved